Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000
polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))
Compound class:
Antibody
Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1]. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2019), EMA (2020)) |
Approved drug? | Yes. FDA (2019) | EMA (2020) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9714 | polatuzumab vedotin |
Synonyms ![]() |
ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000 |
Database Links ![]() |
|
GtoPdb PubChem SID | 252166614 |
Search PubMed clinical trials | polatuzumab vedotin |
Search PubMed titles | polatuzumab vedotin |
Search PubMed titles/abstracts | polatuzumab vedotin |
Wikipedia | Polatuzumab_vedotin |